Bayer Healthcare and Comgenex Extend Drug Discovery Collaboration
"As a result of ComGenex high scientific and quality standards we are glad to continue the collaboration for the coming year. During the past several years ComGenex has built a knowledge base that has great value for Bayer and that we could efficiently utilize in our drug discovery process. The flexibility and expertise of ComGenex in responding to Bayer's high standards shows that ComGenex is a reliable high-quality partner," said Dr. Hanno Wild, Head of Medicinal Chemistry at Bayer HealthCare.
During the extended term ComGenex will focus on further improving the overall properties of compound libraries by applying proprietary design criteria and extending chemical diversity. The provided potentially bioactive compound libraries will be used for applications in all discovery research areas of Bayer HealthCare's pharma division.
"The extension of our collaboration and arrangements shows that the ComGenex chemistry team is committed to satisfy the ever increasing demands of our partners. Our hard work over the years has paid off and we are glad that we were able to build a knowledge base and service portfolio that leading pharmaceutical companies like Bayer can utilize efficiently in their discovery process," said Dr. László Ürge, CEO of ComGenex.
Topics
Organizations
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.